Aim To investigate prognostic significance of preoperative levels of the Carbohydrate anti-gen 19-9 (CA 19-9) in patients with stage III rectal adenocarcinoma who underwent a treatment at the Clinical Centre of the University of Sarajevo. Methods A retrospective cohort study included 84 patients who underwent radical anterior rectal resection due to grade III rectal adenocarcinoma, followed by adjuvant chemotherapy according to the FOLFOX protocol (Oxaliplatin, Leucovorin, 5-Fluorouracil (5-FU)). The patients were divided into two groups according to CA 19-9 values (≥27 U/mL and <27 U/mL, respectively). Results High pre-operative CA 19-9 values predicted an increased probability of postoperative metastases, especially liver, lung and abdominopelvic metastases, as well as three-year disease-free survival (3Y-DFS) and three-year overall survival (3Y-OS). The 3Y-DFS rate for patients with high CA 19-9 was 64.5%, while for those with low CA 19-9 it was 87.2%. The 3Y-OS rate for patients with high CA 19-9 was 89.8%, while for those with low CA 19-9 it was 65.7%. Univariate and multivariate regression analysis confirmed that a high level of CA 19-9 is an independent predictor for DFS and OS shorter than three years. Conclusion Pre-operatively elevated values of CA 19-9 in rectal adenocarcinoma have a significant role in predicting the outcome in patients with stage III rectal adenocarcinoma.
Siegel R, Miller K, Jemal A. Cancer statistics. CA Cancer J Clin. 2018. p. 7–30.
2.
Cancer A. Rectal cancer treatment by stage. Am Cancer Soc.
3.
Chen V, Hsieh MC, Charlton M, Ruiz B, Karlitz J, Altekruse S. Analysis of stage and clinical/prognostic factors for colon and rectal cancer from SEER registries: AJCC and collaborative stage data collection system. Cancer. 2014. p. 3793–806.
4.
Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2020. p. 1291–305.
5.
Giesen L, Olthof P, Elferink M, Verhoef C, Dekker J. Surgery for rectal cancer: Differences in resection rates among hospitals in the Netherlands. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2021. p. 2384–9.
6.
André T, De Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol Off J Am Soc Clin Oncol. 2015. p. 4176–87.
7.
Baxter N, Kennedy E, Bergsland E, Berlin J, George T, Gill S. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. J Clin Oncol Off J Am Soc Clin Oncol. 2022.
8.
p. 892–910.
9.
Grothey A, Sobrero A, Shields A, Yoshino T, Paul J, Taieb J. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med. 2018. p. 1177–88.
10.
Chan A, Prassas I, Dimitromanolakis A, Brand R, Serra S, Diamandis E. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2014. p. 5787–95.
11.
Chen J, Zhao T, Jia S, Zhou S, Zhou L, Wang S. High Expression of P38α and Preoperative Carbohydrate Antigen 19-9 Indicate Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma. J Cancer. 2018. p. 650–9.
12.
Grunnet M, Christensen I, Lassen U, Jensen L, Lydolph M, Knox J. Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer. Eur J Cancer Oxf Engl. 1990. p. 51.
13.
14.
Benson A, Venook A, Al-Hawary M, Cederquist L, Chen YJ, Ciombor K. NCCN Guidelines Insights: Colon Cancer, Version 2. J Natl Compr Cancer Netw JNCCN. 2018. p. 359–69.
15.
Kawamura H, Honda M, Takano Y, Kinuta S, Kamiga T, Saji S. Prognostic Role of Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 in Stage IV Colorectal Cancer. Anticancer Res. 2022. p. 3921–8.
16.
Yu Z, Chen Z, Wu J, Li Z, Wu Y. Prognostic value of pretreatment serum carbohydrate antigen 19-9 level in patients with colorectal cancer: A metaanalysis. PloS One. 2017. p. 188139.
17.
Hidaka E, Maeda C, Nakahara K, Wakamura K, Ishiyama Y, Shimada S. High Serum CA19-9 Concentration Predicts Poor Prognosis in Elderly Patients with Stage IV Colorectal Cancer. Gastrointest Tumors. 2019. p. 117–24.
18.
Chan G, Chee C. Making sense of adjuvant chemotherapy in colorectal cancer. J Gastrointest Oncol. 2019. p. 1183–92.
19.
Inci F, Karatas F. The relationship of preoperative and postoperative serum CEA and CA 19-9 levels with tumor localization, stage and overall survival in patients with colorectal cancer. Ann Med Res. 2021. p. 726.
20.
Serdarevic N. The Comparison Between Different Immunoassays for Serum Carbohydrate Antigen (CA 19-9) Concentration Measurement. Acta Inform Medica AIM J Soc Med Inform Bosnia Herzeg Cas Drustva Za Med Inform BiH. 2018.
21.
p. 235–9.
22.
Li Z, Zhu H, Pang X, Mao Y, Yi X, Li C. Preoperative serum CA19-9 should be routinely measured in the colorectal patients with preoperative normal serum CEA: a multicenter retrospective cohort study. BMC Cancer. 2022. p. 962.
23.
Mcshane J, De A. Retrospective Analysis of the Safety of FOLFOX Compared to CAPOX for Adjuvant Treatment of Stage III Colorectal Cancer in Newfoundland Patients. Gastrointest Disord. 2022. p. 214–22.
24.
Doyle D, Hendrix J, Garmon E. American society of anesthesiologists classification. 2023.
25.
Weiser M. AJCC 8th Edition: Colorectal Cancer. Ann Surg Oncol. 2018. p. 1454–5.
26.
Townsend C, Beauchamp R, Evers B. Sabiston Textb. Surg. 21st edition. Elsevier; 2022. p. 1381.
27.
Motoi F, Murakami Y, Okada KI, Matsumoto I, Uemura K, Satoi S. Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma. World J Surg. 2019. p. 43.
28.
p. 634–41.
29.
Hong S, Song K, Hwang D, Lee J, Lee W, Jun E. Preoperative serum carbohydrate antigen 19-9 levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma. World J Gastrointest Surg. 2021. p. 1423–35.
30.
Zhou W, Yang F, Peng J, Wang F, Lin Y, Jiang W. High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy. J Cancer. 2019. p. 3810–8.
31.
Kurniawan A, Lusikooy R, Mappincara M, Rauf M, Labeda I, Warsinggih W. The relationship between triple tumor marker (CEA, CA 19-9, and CA 125) and colorectal cancer metastases at Makassar, Indonesia. Int J Med Rev Case Rep. 2020. p. 1.
32.
Subki A, Buttns A, Alkahtani A. CEA and CA19-9 levels and KRAS mutation status as biomarkers for colorectal cancer. Clin Oncol. 2021. p. 1–8.
33.
Wang J, Li S, Liu Y, Zhang C, Li H, Lai B. Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population-based analysis. Cancer Med. 2020. p. 361–73.
34.
Patel S. Med News Today 2023. 2023.
35.
Bostancı M, Mollaoğlu M, Karadayı K. Relationship Between Serum CA 19-9 Levels and Lymphovascular and Perineural Invasion of the Tumor and Lymph Node Metastasis in Patients Operated due to Pancreatic Carcinoma. J Ank Univ Fac Med. 2022. p. 113–8.
36.
Desai S, Guddati A, Carcinoembryonic Antigen. Carbohydrate Antigen 19-9. Cancer Antigen. 2023. p. 4–14.
37.
Lin PC, Lin JK, Lin CC, Wang HS, Yang SH, Jiang JK. Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis. Int J Colorectal Dis. 2012. p. 1333–8.
38.
Shin J, Kim H, Lee W, Yun S, Cho Y, Huh J. High preoperative serum CA 19-9 levels can predict poor oncologic outcomes in colorectal cancer patients on propensity score analysis. Ann Surg Treat Res. 2019. p. 107–15.
39.
Lakemeyer L, Sander S, Wittau M, Henne-Bruns D, Kornmann M, Lemke J. Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer. Dis Basel Switz. 2021. p. 21.
40.
Graziosi L, Elisabetta M, Rebonato A, Donini A. Preoperative Serum Markers Prognostic Evaluation in Colon Cancer Patients. J Cancer Sci Ther. 2018.
41.
Li Y, Hua R, He J, Zhang H. Survival Contradiction in Stage II, IIIA, And IIIB Colon Cancer: A Surveillance. Epidemiology, and End Result-Based Analysis. Evid-Based Complement Altern Med ECAM. 2022. p. 4088117.
42.
Murcia O, Juárez M, Rodríguez-Soler M, Hernández-Illán E, Giner-Calabuig M, Alustiza M. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy. PloS One. 2018. p. 203051.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
